Neurogene aims to raise capital through a public offering, including pre-funded warrants for certain investors.
Neurogene Inc (NGNE) has launched a public offering of common stock, with select investors eligible to receive pre-funded warrants in lieu of shares. The company plans to grant underwriters a 30-day option to purchase additional shares to cover over-allotments.
All securities in the offering are being sold by Neurogene, which has not yet disclosed the total size or expected proceeds. The move follows recent capital-raising efforts in the biotech sector amid volatile market conditions.
Shares of Neurogene were halted pending the announcement, with trading expected to resume later in the session.